https://www.qynapse.com/wp-content/uploads/2020/11/RSNA-thumbnail2.png 1125 1640 ysalledechou https://www.qynapse.com/wp-content/uploads/2019/06/Qynapse_HD.png ysalledechou2020-11-24 13:30:532020-11-24 15:38:05QYNAPSE to sponsor and exhibit at the 106th RSNA Annual Meeting and present its latest AI-neuroimaging advancements, which are transforming care for patients with brain disorders
QYNAPSE is pleased to sponsor the 106th Radiology Society of North America (RSNA) Annual Meeting. This year, QYNAPSE is presenting its latest technological advancements of its QyScore® medical device and will also showcase significant developments being made with its QyPredict® AI prediction technology, which is transforming central nervous system (CNS) clinical trials.
https://www.qynapse.com/wp-content/uploads/2020/11/Matt-Ullum-Thumbnail.png 1125 1641 ysalledechou https://www.qynapse.com/wp-content/uploads/2019/06/Qynapse_HD.png ysalledechou2020-11-12 08:00:222020-11-12 08:29:34QYNAPSE appoints Matt Ullum as Chief Commercial Officer to drive and accelerate its growth globally
QYNAPSE appoints Matt Ullum, CPA, MBA as Chief Commercial Officer. In his new role, Matt assumes overall responsibility for both sales and marketing to accelerate the commercialization of QYNAPSE’s solutions globally. Matt is bringing over 15 years of experience spanning the global pharmaceutical and healthcare industries with a focus on central nervous system (CNS) disorders.
https://www.qynapse.com/wp-content/uploads/2020/11/CTAD-thumbnail5.png 1125 1640 ysalledechou https://www.qynapse.com/wp-content/uploads/2019/06/Qynapse_HD.png ysalledechou2020-11-03 09:46:032020-11-03 10:00:10QyPredict®: an AI prediction technology for optimizing patient selection in clinical trials to be presented at the CTAD Conference by QYNAPSE
QYNAPSE will present results on QyPredict®, an AI prediction technology for patient selection in Alzheimer’s clinical trials, at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference. The software computes a cognitive decline risk score that can be used to enrich patient selection strategy with the aim to increase clinical trial success probability.
https://www.qynapse.com/wp-content/uploads/2020/10/Qynapse-TPMD-thumbnail.png 1125 1400 ysalledechou https://www.qynapse.com/wp-content/uploads/2019/06/Qynapse_HD.png ysalledechou2020-10-13 07:09:222020-10-13 07:11:04QYNAPSE (France) and TRUE POSITIVE MEDICAL DEVICES (Canada) are partnering to provide the most advanced AI platform for brain diseases
QYNAPSE today announces the acquisition of the Canadian company TRUE POSITIVE MEDICAL DEVICES Inc. (TPMD), a spin-off from the universities of McGill and Laval – to form the most advanced artificial intelligence (AI) platform in the field of imaging of brain diseases such as Alzheimer's, Parkinson's and multiple sclerosis.
https://www.qynapse.com/wp-content/uploads/2020/09/World-Alzheimer-Day_brain_website.png 703 1641 ysalledechou https://www.qynapse.com/wp-content/uploads/2019/06/Qynapse_HD.png ysalledechou2020-09-21 07:43:142020-09-21 07:43:14World Alzheimer's Day: Neuroimaging and artificial intelligence offer new opportunities for patients
Qynapse is strongly committed to innovation in the field of neurodegenerative diseases, particularly Alzheimer's. "By combining the latest advances in neuroimaging and artificial intelligence algorithms, our solutions represent powerful tools for the diagnosis, disease monitoring and patient care for Alzheimer's disease."
https://www.qynapse.com/wp-content/uploads/2020/10/MS-data-thumbnail-v4.png 1125 1400 ysalledechou https://www.qynapse.com/wp-content/uploads/2019/06/Qynapse_HD.png ysalledechou2020-09-16 16:33:552020-10-12 10:37:54Qynapse releases new data demonstrating the value of QyScore® for the clinical assessment of Multiple Sclerosis (MS)
These results confirmed that the use of a normative database for the interpretation of brain volumetric analysis, such as the QyScore® normative database, can improve the individual assessment of brain neurodegeneration in RRMS patients in the clinical routine setting.